Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yinqiaosan-Maxingganshitang in Mild and Moderate COVID-19
NCT05787327Phase 2Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- May 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of yinqiaosan + maxingganshitang in coronavirus disease 2019 (COVID-19), sponsored by The Chinese University of Hong Kong. Started May 2023; status: recruiting.
02
Drugs
yinqiaosan + maxingganshitang
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05787327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787327.